跳到正文
原文
The Lancet HIV· Beatriz Grinsztejn, Thiago Silva Torres, Brenda Hoagland, Carolina Coutinho, Mayara Secco Torres Silva, Iuri Costa Leite, Marcelo Cunha, Monica Derrico, Emilia M Jalil, Sandra Wagner Cardoso, Roberta Trefiglio, Alessandro Farias, Maria Paula G Mourão, José Valdez Madruga, Josué N de Lima, Ronaldo Zonta, Gabrielle O’Malley, Julio Moreira, Keila Simpson, Alex R Rinehart, Nanlesta Pilgrim, Anna Hellstrom, Anne-Isabelle Cameron, Paula Mendes Luz, Raphael J Landovitz, Marcos Benedetti, Cristina Pimenta, Ronaldo Ismério Moreira, Valdilea Gonçalves Veloso, the ImPrEP CAB Brasil Study Group·· 2026-09-25AI 评分32

Integrating Long-Acting Cabotegravir into Brazilian Public Health System

[Articles] Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system (ImPrEP CAB Brasil): a hybrid type-2 implementation-effectiveness cohort study

AI 导读

同日注射长效卡博特拉韦(CAB-LA)有效降低了HIV感染率并提高了预防覆盖率,支持在巴西 SUS(国家公共卫生系统)中实施长效选项。

来源:The Lancet HIV · thelancet.com